Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA05 TACROLIMUSUM CAPS. ELIB. PREL 0,5 mg
ADVAGRAF 0,5 mg 0,5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. 0.5 mg
PROGRAF(R) 0,5 mg 0.5 mg ASTELLAS PHARMA GMBH
Prescriere limitată: Profilaxia rejetului de alogrefă la adulţii cu transplant cardiac
L04AA05 TACROLIMUSUM CAPS. 1 mg
PROGRAF(R) 1 mg 1 mg ASTELLAS IRELAND CO. LTD.
Prescriere limitată: Profilaxia rejetului de alogrefă la adulţii cu transplant cardiac
L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 1 mg
ADVAGRAF 1 mg 1 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. 5 mg
PROGRAF(R) 5 mg 5 mg ASTELLAS PHARMA GMBH
Prescriere limitată: Profilaxia rejetului de alogrefă la adulţii cu transplant cardiac
L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 5 mg
ADVAGRAF 5 mg 5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CONC. PT. SOL. PERF. 5 mg/ml
PROGRAF(R) 5 mg/ml 5 mg/ml ASTELLAS PHARMA GMBH
Prescriere limitată: Profilaxia rejetului de alogrefă la adulţii cu transplant cardiac
________________________________________________________________________________
______________________________________________________________________________
| 936 |L04AA06| MYCOPHENOLATUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA06 MYCOPHENOLATUM COMPR. FILM. GASTROREZ. 180 mg
MYFORTIC 180 mg 180 mg NOVARTIS PHARMA GMBH
L04AA06 MYCOPHENOLATUM PULB. PT. SUSP. ORALA 1 g/5 ml
CELLCEPT 1 mg/5 ml 1 g/5 ml ROCHE REGISTRATION LTD.
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen cardiac.
L04AA06 MYCOPHENOLATUM CAPS. 250 mg
CELLCEPT 250 mg 250 mg ROCHE REGISTRATION LTD.
MYFENAX 250 mg 250 mg TEVA PHARMA BV
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen cardiac.
L04AA06 MYCOPHENOLATUM COMPR. FILM. GASTROREZ. 360 mg
MYFORTIC 360 mg 360 mg NOVARTIS PHARMA GMBH
L04AA06 MYCOPHENOLATUM CAPS. 500 mg
MYFENAX 500 mg 500 mg TEVA PHARMA BV
L04AA06 MYCOPHENOLATUM COMPR. FILM. 500 mg
CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD.
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen cardiac.
L04AA06 MYCOPHENOLATUM PULB. PT. CONC. PT. 500 mg
SOL. PERF.
CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD.
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen cardiac.
________________________________________________________________________________
SUBLISTA C2 - P9: PROGRAM NAŢIONAL DE TRANSPLANT DE ORGANE, ŢESUTURI ŞI CELULE DE ORIGINE UMANĂ. P9.3 TRANSPLANT HEPATIC
______________________________________________________________________________
| 937 |A05AA02| ACIDUM URSODEOXYCHOLICUM | |
|_______|_______|____________________________________________|_________________|
NOTĂ:
Nu se va prescrie în regim compensat pentru tratamentul litiazei biliare.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
A05AA02 ACIDUM CAPS. 250 mg
URSODEOXYCHOLICUM
URSOFALK(R) 250 mg DR. FALK PHARMA GMBH
URSOSAN 250 mg PRO. MED. CS PRAHA AS
________________________________________________________________________________
______________________________________________________________________________
| 938 |B01AB05| ENOXAPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti-Xa/0.2 ml
CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS
anti-Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti-Xa/0,4 ml
CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS
anti-Xa/0.4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti-Xa/0.6 ml
CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS
anti-Xa/0.6 ml
B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui
anti-Xa/0.8 ml
CLEXANE 8000 ui 8000 ui anti-Xa/0.8 ml LAB. AVENTIS
anti-Xa/0.8 ml
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti-Xa/0.2 ml
CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS
anti-Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti-Xa/0,4 ml
CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS
anti-Xa/0.4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti-Xa/0.6 ml
CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS
anti-Xa/0.6 ml
________________________________________________________________________________
______________________________________________________________________________
| 939 |B01AB08| REVIPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml
CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
B01AB08 REVIPARINUM SOL. INJ. 3436 ui/0.6 ml
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG
________________________________________________________________________________
______________________________________________________________________________
| 940 |B01AC11| ILOPROSTUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AC11 ILOPROSTUM CONC. PT. SOL. PERF. 20 µg/ml
ILOMEDIN(R) 20 20 µg/ml SCHERING AG
________________________________________________________________________________
______________________________________________________________________________
| 941 |B01AD02| ALTEPLASUM** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AD02 ALTEPLASUM LIOF. + SOLV. PT. SOL. 50 mg
INJ.
ACTILYSE 50 mg BOEHRINGER INGELHEIM INT.
GMBH
________________________________________________________________________________
______________________________________________________________________________
| 944 |C03EB01| COMBINAŢII (SPIRONOLACTONUM + FUROSEMIDUM) | |
|_______|_______|____________________________________________|_________________|
Electroliţii serici trebuie să fie verificaţi periodic.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
C03EB01 COMBINAŢII CAPS.
(SPIRONOLACTONUM +
FUROSEMIDUM)
DIUREX 50 TERAPIA SA
________________________________________________________________________________
______________________________________________________________________________
| 945 |H01BA02| DESMOPRESSINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
H01BA02 DESMOPRESSINUM
MINIRIN 0,2 mg 0.2 mg FERRING AB
H01BA02 DESMOPRESSINUM COMPR. 0.2 mg
MINIRIN 0,2 mg 0.2 mg FERRING AB
________________________________________________________________________________
______________________________________________________________________________
| 946 |J01CR05| PIPERACILLINUM + TAZOBACTAMUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01CR05 PIPERACILLINUM + LIOF. PT. SOL. INJ.
TAZOBACTAMUM
TAZOCIN 2,25 WYETH LEDERLE PHARMA GMBH
TAZOCIN 4,5 WYETH LEDERLE PHARMA GMBH
________________________________________________________________________________
______________________________________________________________________________
| 947 |J01XX08| LINEZOLIDUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA 100 mg/5 ml
ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM SOL. PERF. 2 mg/ml
ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM COMPR. FILM. 600 mg
ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG
________________________________________________________________________________
______________________________________________________________________________
| 948 |J02AC03| VORICONAZOLUM** | Protocol: J012B |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J02AC03 VORICONAZOLUM COMPR. FILM. 200 mg
VFEND 200 mg 200 mg PFIZER LTD.
J02AC03 VORICONAZOLUM PULB. PT. SOL. PERF. 200 mg
VFEND 200 mg 200 mg PFIZER LTD.
J02AC03 VORICONAZOLUM PULB. PT. SUSP. ORALA 40 mg/ml
VFEND 40 mg/ml 40 mg/ml PFIZER LTD.
J02AC03 VORICONAZOLUM COMPR. FILM. 50 mg
VFEND 50 mg 50 mg PFIZER LTD.
________________________________________________________________________________
______________________________________________________________________________
| 949 |J02AX04| CASPOFUNGINUM** | Protocol: J010D |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 50 mg
SOL. PERF.
CANCIDAS 50 mg 50 mg MERCK SHARP & DOHME LTD
J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 70 mg
SOL. PERF.
CANCIDAS 70 mg 70 mg MERCK SHARP & DOHME LTD
________________________________________________________________________________
______________________________________________________________________________
| 951 |J05AB14| VALGANCICLOVIRUM** | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul de iniţiere şi menţinere pentru retinita cu citomegalovirus (CMV) la pacienţi imunocompromişi.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J05AB14 VALGANCICLOVIRUM COMPR. FILM. 450 mg
VALCYTE(R) 450 mg 450 mg ROCHE ROMANIA SRL
________________________________________________________________________________
______________________________________________________________________________
| 953 |L03AA02| FILGRASTIMUM (G-CSF) | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 30 MU/0.5 ml
NEUPOGEN(R) 30 MU/0.5 ml AMGEN EUROPE B.V.
L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 48 MU/0.5 ml
NEUPOGEN(R) 48 MU/0.5 ml AMGEN EUROPE B.V.
________________________________________________________________________________
______________________________________________________________________________
| 954 |L04AA01| CICLOSPORINUM | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Managementul rejectului de grefă la pacienţii supuşi procedurii de transplant.
Monitorizarea atentă a pacienţilor este obligatorie.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA01 CICLOSPORINUM CAPS. MOI 100 mg
EQUORAL(R) 100 mg 100 mg IVAX - PHARMACEUTICALS
S.R.O.
L04AA01 CICLOSPORINUM SOL. ORALA 100 mg/ml
EQUORAL(R) 100 mg/ml IVAX - PHARMACEUTICALS
S.R.O.
SANDIMMUN NEORAL(R) 100 mg/ml NOVARTIS PHARMA GMBH
L04AA01 CICLOSPORINUM CAPS. MOI 25 mg
CICLORAL(R) HEXAL(R) 25 mg 25 mg HEXAL AG
EQUORAL(R) 25 mg 25 mg IVAX - PHARMACEUTICALS
S.R.O.
SANDIMMUN NEORAL(R) 25 mg NOVARTIS PHARMA GMBH
L04AA01 CICLOSPORINUM CAPS. MOI 50 mg
CICLORAL(R) HEXAL 50 mg 50 mg HEXAL AG
EQUORAL(R) 50 mg 50 mg IVAX - PHARMACEUTICALS
S.R.O.
SANDIMMUN NEORAL(R) 50 mg NOVARTIS PHARMA GMBH
________________________________________________________________________________
______________________________________________________________________________
| 955 |L04AA05| TACROLIMUSUM** | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul rejetului de alogrefă rezistent la alte
terapii imunosupresoare, la pacienţii adulţi.
Profilaxia rejetului de grefă la pacienţii care primesc
transplant hepatic alogen.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA05 TACROLIMUSUM CAPS. ELIB. PREL 0,5 mg
ADVAGRAF 0,5 mg 0,5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. 0.5 mg
PROGRAF(R) 0,5 mg 0.5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. 1 mg
PROGRAF(R) 1 mg 1 mg ASTELLAS IRELAND CO. LTD.
L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 1 mg
ADVAGRAF 1 mg 1 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. 5 mg
PROGRAF(R) 5 mg 5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 5 mg
ADVAGRAF 5 mg 5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CONC. PT. SOL. PERF. 5 mg/ml
PROGRAF(R) 5 mg/ml 5 mg/ml ASTELLAS PHARMA GMBH
________________________________________________________________________________
______________________________________________________________________________
| 956 |L04AA06| MYCOPHENOLATUM** | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA06 MYCOPHENOLATUM COMPR. FILM. GASTROREZ. 180 mg
MYFORTIC 180 mg 180 mg NOVARTIS PHARMA GMBH
L04AA06 MYCOPHENOLATUM PULB. PT. SUSP. ORALA 1 g/5 ml
CELLCEPT 1 mg/5 ml 1 g/5 ml ROCHE REGISTRATION LTD.
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic
L04AA06 MYCOPHENOLATUM CAPS. 250 mg
CELLCEPT 250 mg 250 mg ROCHE REGISTRATION LTD.
MYFENAX 250 mg 250 mg TEVA PHARMA BV
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic
L04AA06 MYCOPHENOLATUM COMPR. FILM. GASTROREZ. 360 mg
MYFORTIC 360 mg 360 mg NOVARTIS PHARMA GMBH
L04AA06 MYCOPHENOLATUM CAPS. 500 mg
MYFENAX 500 mg 500 mg TEVA PHARMA BV
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic
L04AA06 MYCOPHENOLATUM COMPR. FILM. 500 mg
CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD.
L04AA06 MYCOPHENOLATUM PULB. PT. CONC. PT. 500 mg
SOL. PERF.
CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD.
________________________________________________________________________________
______________________________________________________________________________
| 957 |L04AA10| SIROLIMUS** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA10 SIROLIMUS COMPR. FILM. 1 mg
RAPAMUNE 1 mg 1 mg WYETH EUROPA LTD.
Monitorizarea atentă a pacienţilor este obligatorie
________________________________________________________________________________
SUBLISTA C2 - P9: PROGRAM NAŢIONAL DE TRANSPLANT DE ORGANE, ŢESUTURI ŞI CELULE DE ORIGINE UMANĂ. P9.4 TRANSPLANT RENAL, TRANSPLANT COMBINAT RINICHI ŞI PANCREAS
______________________________________________________________________________
| 958 |A05AA02| ACIDUM URSODEOXYCHOLICUM | |
|_______|_______|____________________________________________|_________________|
NOTĂ:
Nu se va prescrie în regim compensat pentru tratamentul litiazei biliare
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
A05AA02 ACIDUM CAPS. 250 mg
URSODEOXYCHOLICUM
URSOFALK(R) 250 mg DR. FALK PHARMA GMBH
URSOSAN 250 mg PRO. MED. CS PRAHA AS
________________________________________________________________________________
______________________________________________________________________________
| 959 |A11CC03| ALFACALCIDOLUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
A11CC03 ALFACALCIDOLUM CAPS. MOI 0.25 µg
ALPHA D3 0,25 µg 0.25 µg TEVA PHARMACEUTICALS SRL
A11CC03 ALFACALCIDOLUM CAPS. MOI 0.50 µg
ALPHA D3 0.50 µg 0.50 µg TEVA PHARMACEUTICALS SRL
________________________________________________________________________________
______________________________________________________________________________
| 960 |B01AB05| ENOXAPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti-Xa/0.2 ml
CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS
anti-Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti-Xa/0,4 ml
CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS
anti-Xa/0.4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti-Xa/0.6 ml
CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS
anti-Xa/0.6 ml
B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui
anti-Xa/0.8 ml
CLEXANE 8000 ui 8000 ui anti-Xa/0.8 ml LAB. AVENTIS
anti-Xa/0.8 ml
B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui
anti-Xa/0.2 ml
CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS
anti-Xa/0.2 ml
B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui
anti-Xa/0,4 ml
CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS
anti-Xa/0.4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui
anti-Xa/0.6 ml
CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS
anti-Xa/0.6 ml
________________________________________________________________________________
______________________________________________________________________________
| 961 |B01AB04| DALTEPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB04 DALTEPARINUM SOL. INJ. 10000 ui/ml
FRAGMIN 10000 UI/ml 10000 ui/ml PFIZER EUROPE MA EEIG
B01AB04 DALTEPARINUM SOL. INJ. 15000 ui/0.6 ml
FRAGMIN 15000 UI/0,6 ml 15000 ui/0.6 ml PFIZER EUROPE MA EEIG
B01AB04 DALTEPARINUM SOL. INJ. 2500 ui/0.2 ml
FRAGMIN 2500 UI/0,2 ml 2500 ui/0.2 ml PFIZER EUROPE MA EEIG
B01AB04 DALTEPARINUM SOL. INJ. 5000 ui/0.2 ml
FRAGMIN 5000 UI/0,2 ml 5000 ui/0.2 ml PFIZER EUROPE MA EEIG
B01AB04 DALTEPARINUM SOL. INJ. 7500 ui/0.3 ml
FRAGMIN 7500 UI/0,3 ml 7500 ui/0.3 ml PFIZER EUROPE MA EEIG
________________________________________________________________________________
______________________________________________________________________________
| 962 |B01AB08| REVIPARINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml
CLIVARIN(R) 1432 UI/0,25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
B01AB08 REVIPARINUM SOL. INJ. 3436 ui/0.6 ml
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG
________________________________________________________________________________
#M4
______________________________________________________________________________
| 963 | *** Abrogată |
|_______|______________________________________________________________________|
______________________________________________________________________________
| 964 | *** Abrogată |
|_______|______________________________________________________________________|
#B
______________________________________________________________________________
| 965 |B05AA06| POLYGELINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
B05AA06 POLYGELINUM SOL. PERF. 3.5%
HAEMACCEL 3.5% THERASELECT GMBH
________________________________________________________________________________
______________________________________________________________________________
| 966 |H01CB02| OCTREOTIDUM** | Protocol: H010C |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
H01CB02 OCTREOTIDUM SOL. INJ. 0.1 mg/ml
SANDOSTATIN(R) 0.1 mg/ml NOVARTIS PHARMA GMBH
H01CB02 OCTREOTIDUM PULB. + SOLV. PT. SUSP. 10 mg
INJ. (I.M.) CU ELIB.
PRELUNG.
SANDOSTATIN LAR 10 mg 10 mg NOVARTIS PHARMA GMBH
H01CB02 OCTREOTIDUM PULB. + SOLV. PT. SUSP. 20 mg
INJ. (I.M.) CU ELIB.
PRELUNG.
SANDOSTATIN LAR 20 mg 20 mg NOVARTIS PHARMA GMBH
H01CB02 OCTREOTIDUM PULB. + SOLV. PT. SUSP. 30 mg
INJ. (I.M.) CU ELIB.
PRELUNG.
SANDOSTATIN LAR 30 mg 30 mg NOVARTIS PHARMA GMBH
________________________________________________________________________________
______________________________________________________________________________
| 967 |J01CR05| PIPERACILLINUM + TAZOBACTAMUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01CR05 PIPERACILLINUM + LIOF. PT. SOL. INJ.
TAZOBACTAMUM
TAZOCIN 2,25 WYETH LEDERLE PHARMA GMBH
TAZOCIN 4,5 WYETH LEDERLE PHARMA GMBH
________________________________________________________________________________
______________________________________________________________________________
| 968 |J01XA02| TEICOPLANINUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01XA02 TEICOPLANINUM LIOF. + SOLV. PT. SOL. 400 mg
INJ.
TARGOCID(R) 400 mg 400 mg AVENTIS PHARMA LTD.
________________________________________________________________________________
______________________________________________________________________________
| 969 |J01XX08| LINEZOLIDUM | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA 100 mg/5 ml
ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM SOL. PERF. 2 mg/ml
ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM COMPR. FILM. 600 mg
ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG
________________________________________________________________________________
______________________________________________________________________________
| 970 |J02AB02| KETOCONAZOLUM | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Candidoza genitală simptomatică recurentă după
Dostları ilə paylaş: |